Definitive Contract 75F40123C00201
Award Date
9/21/23
Potential Completion Date
9/20/25
Potential Value
$687K
Federal Agency
Food and Drug Administration
Awardee
University Of Sydney
Ultimate Awardee
Not listed
NAICS Category
541690 - Other Scientific and Technical Consulting Services
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Australia
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a Firm Fixed Price Definitive Contract to the University of Sydney, doing business as the International Clinical Trials Symposium, to "IMPROVE SCIENTIFIC APPROACHES TO EVALUATE GENERIC DRUGS". The contract, valued at $1,234,519.00, has an ultimate completion date of September 29, 2025. The University of Sydney is a leading Australian educational institution that frequently collaborates with U.S. agencies and research organizations...
The Food and Drug Administration (FDA) awarded a $4,935,108 definitive contract to the Commonwealth Scientific and Industrial Research Organisation (CSIRO), a non-profit research organization based in Australia. The contract is for a scientific research study entitled "Strengthening COVID-19 Animal Models and Regulatory Science Using a Systems Biology Approach." This contract was awarded under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which aims to...
The Food and Drug Administration (FDA) awarded a $554,827 firm fixed-price contract to The University of Auckland Research Office Division, a non-profit educational institution based in New Zealand. The contract is for the development of in-vitro tools to simulate the chewing of pharmaceutical opioid drug products. This work will help the FDA evaluate the swallowability and other critical attributes of opioid medications. The contract does not have a set-aside designation, indicating the...
This definitive firm fixed-price contract, valued at $249,582.00, was awarded by the Food and Drug Administration (FDA) to the University of Southern California (USC) to support literature research necessary to identify potential areas to study. The contract has a completion date of December 31, 2024 and was issued without a set-aside designation. USC, a prestigious private research university, regularly performs work for the federal government through contract and grant awards managed by its...
The U.S. Food and Drug Administration (FDA) awarded a $1,530,889.00 definitive, cost-no-fee contract to the University of Connecticut (UConn) to conduct research on "Investigating the Impact of API Purity, Excipient Source and Manufacturing Process on Performance and Quality of Complex siRNA Lipid Nanoparticles". This is a 4-year contract running from September 2023 to September 2027. UConn, a non-profit research university, will be the prime contractor with no set-aside designation....
The U.S. Food and Drug Administration (FDA) awarded a $696,359 firm-fixed-price contract to Duke University's Office of Research Administration Division to conduct research and development activities in support of regulatory science and innovation. The contract, which does not have a set-aside designation, originated from a Broad Agency Announcement (BAA) that solicits advanced proposals across nine key areas to advance scientific knowledge in support of the FDA's mission to protect public...
The Food and Drug Administration (FDA) awarded a $527,318.00 definitive contract to Uppsala Universitet, a Swedish educational institution, to conduct research and development on model-integrated strategies for bioequivalence evaluation of drugs with high variability and/or long half-life. This contract was awarded under the FDA's Broad Agency Announcement, which seeks proposals to advance regulatory science in various areas. The contract has no set-aside designation and is intended to support...
The U.S. Food and Drug Administration (FDA) awarded a $296,477.00 definitive contract to the University of Florida (UF) Division of Sponsored Research for research related to "REAL-TIME RISK STRATIFICATION FOR HYPO- OR HYPERGLYCEMIA TO ENHANCE GLUCOSE MANAGEMENT OUTCOMES IN HOSPITALS." The contract, which is not set-aside, has a completion date of September 29, 2017. UF, a major research institution, has an extensive portfolio of federal contract and grant awards across various...
This federal contract award, identified as HHSF223201610099C, was made by the Food and Drug Administration (FDA) to the University of Florida (UF) Division of Sponsored Research. The contract, valued at $764,975.37, is for a Pharmacokinetic Comparison of Locally Acting Orally Inhaled Drug Products. This work falls under the FDA's Broad Agency Announcement (BAA) program for this research area. The contract is a definitive, cost-no-fee contract, with a performance period ending on March 22,...
The U.S. Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $350,353 definitive contract to Northwestern University, a private research university, for a project related to patient-focused drug development (PFDD) in oncology. This contract was issued under the FDA's Oncology Center of Excellence's PFDD program, which identifies research into measurement of patient experiences. Northwestern University is serving as the prime contractor, with the...